Jade Biosciences, Inc.
- JBIO ยท Nasdaq
- Pharmaceutical Preparations
- Waltham, MA
- 55 employees
- CIK 0001798749
Updated from SEC filings through
Top things to know
Executives
-
Tom Frohlich Chief Executive Officer & Director 10-K, March 6, 2026 - Bradford D. Dahms Chief Financial Officer Form 4, February 13, 2026
What leadership is saying
“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones”
Earnings press release (8-K Ex. 99.1), filed November 13, 2026
Jade Biosciences, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Waltham, MA. It trades as JBIO on Nasdaq. It reported about 55 employees.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | Not on file | Not on file | Not on file | Not on file | Not on file |
| Operating income | -$114M 10-K, 2026-03-06 | -$74.6M 10-K, 2025-03-27 | -$81.4M 10-K, 2025-03-27 | -$53.2M 10-K, 2024-03-25 | -$23.0M 10-K, 2023-03-29 |
| SG&A | $20.4M 10-K, 2026-03-06 | $21.4M 10-K, 2025-03-27 | $17.2M 10-K, 2025-03-27 | $14.6M 10-K, 2024-03-25 | $8.0M 10-K, 2023-03-29 |
| Net income | -$127M 10-K, 2026-03-06 | -$69.6M 10-K, 2025-03-27 | -$75.5M 10-K, 2025-03-27 | -$51.5M 10-K, 2024-03-25 | -$23.0M 10-K, 2023-03-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | Chief Executive Officer & Director | 10-K, March 6, 2026 |
| Bradford D. Dahms | Chief Financial Officer | Form 4, February 13, 2026 |
| Erin Lavelle | Director | 10-K, March 6, 2026 |
| Tomas Kiselak | Director | 10-K, March 6, 2026 |
What Jade Biosciences, Inc. does
We are a clinical-stage biopharmaceutical company developing novel biologic therapies for patients living with autoimmune diseases. Our goal is to improve meaningfully upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 69.2 million (as of November 6, 2026) | 10-Q, November 13, 2026 |
|---|---|---|
| Public float | $289M (as of June 30, 2025) | 10-K, March 6, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 13, 2026 |
| Latest proxy statement | Meeting June 9, 2026 (filed April 28, 2026) | DEF 14A, April 28, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Boston, Massachusetts) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-11-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-30
- Item 8.01 Other events
- 8-K filed 2026-08-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-01
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-06-26
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-11
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-06-04
- Item 8.01 Other events
- 8-K filed 2026-06-01
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-22
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Jade Biosciences, Inc.
- What does Jade Biosciences, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a clinical-stage biopharmaceutical company developing novel biologic therapies for patients living with autoimmune diseases. Our goal is to improve meaningfully upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity."
- How many employees does Jade Biosciences, Inc. have?
- About 55 as of December 31, 2025, as stated in its annual report.
- Who is the CFO of Jade Biosciences, Inc.?
- Bradford D. Dahms, Chief Financial Officer, as named in a 4 filed February 13, 2026.
- Where is Jade Biosciences, Inc. headquartered?
- Waltham, MA.
- What is Jade Biosciences, Inc.'s stock ticker?
- JBIO on Nasdaq.
- What industry is Jade Biosciences, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Jade Biosciences, Inc.'s website?
- jadebiosciences.com. Investor relations: https://jadebiosciences.com/investors/.
- When does Jade Biosciences, Inc. report earnings next?
- February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Jade Biosciences, Inc. a public company?
- Yes. Jade Biosciences, Inc. files with the SEC under CIK 0001798749 and trades as JBIO.
- Who audits Jade Biosciences, Inc.?
- PricewaterhouseCoopers LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Jade Biosciences, Inc. are outstanding?
- 69.2 million shares as of November 6, 2026, from its 10-Q filed November 13, 2026.
- What is Jade Biosciences, Inc.'s public float?
- $289M as of June 30, 2025, as reported on the cover of its 10-K filed March 6, 2026.
- How many business segments does Jade Biosciences, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 13, 2026.
- When is Jade Biosciences, Inc.'s annual shareholder meeting?
- June 9, 2026, per its proxy statement (DEF 14A) filed April 28, 2026.